These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16513012)

  • 1. Hormone replacement therapy with estradiol and drospirenone: an overview of the clinical data.
    Whitehead M
    J Br Menopause Soc; 2006 Mar; 12 Suppl 1():4-7. PubMed ID: 16513012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new hormone replacement therapy containing a progestogen with anti-mineralocorticoid activity.
    Stevenson JC
    J Br Menopause Soc; 2006 Mar; 12 Suppl 1():8-10. PubMed ID: 16513013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
    Archer DF; Thorneycroft IH; Foegh M; Hanes V; Glant MD; Bitterman P; Kempson RL
    Menopause; 2005; 12(6):716-27. PubMed ID: 16278615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levonorgestrel intrauterine system for endometrial protection.
    Sturdee D
    J Br Menopause Soc; 2006 Mar; 12 Suppl 1():1-3. PubMed ID: 16513011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estradiol + drospirenone.
    Prescrire Int; 2007 Jun; 16(89):106. PubMed ID: 17590905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study.
    Wells M; Sturdee DW; Barlow DH; Ulrich LG; O'Brien K; Campbell MJ; Vessey MP; Bragg AJ
    BMJ; 2002 Aug; 325(7358):239. PubMed ID: 12153918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women.
    Genazzani AR; Schmelter T; Schaefers M; Gerlinger C; Gude K
    Climacteric; 2013 Aug; 16(4):490-8. PubMed ID: 23531117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drospirenone and estradiol: a new option for the postmenopausal woman.
    Archer DF
    Climacteric; 2007 Feb; 10 Suppl 1():3-10. PubMed ID: 17364592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 0.5 vs. 1.0 mg estradiol in combination with drospirenone for the treatment of hot flushes.
    Gerlinger C; Gude K; Schmelter T; Schaefers M; Endrikat J
    Climacteric; 2015; 18(4):512-7. PubMed ID: 26000627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism.
    Palacios S; Foidart JM; Genazzani AR
    Maturitas; 2006 Nov; 55(4):297-307. PubMed ID: 16949774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drospirenone in HRT?
    Drug Ther Bull; 2009 Apr; 47(4):41-4. PubMed ID: 19357298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Basic principles of hormone replacement therapy in the postmenopause].
    Dören M
    Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
    Oelkers WH
    Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of drospirenone/estradiol on steroid receptors and Bcl-2 in the postmenopausal endometrium.
    Lima SM; Reis BF; Yamada SS; Postigo S; Grande RM; Botogoski SR; Campaner AB; Hueb CK; Galvão MA
    Climacteric; 2011 Oct; 14(5):551-7. PubMed ID: 21469974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of nonoral estradiol-micronized progesterone or low-dose oral estradiol-drospirenone therapy on metabolic variables and markers of endothelial function in early postmenopause.
    Casanova G; Radavelli S; Lhullier F; Spritzer PM
    Fertil Steril; 2009 Aug; 92(2):605-12. PubMed ID: 18706557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women.
    Cayan F; Dilek U; Pata O; Dilek S
    J Sex Med; 2008 Jan; 5(1):132-8. PubMed ID: 17961145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drospirenone-containing hormone therapy for postmenopausal women. Perspective on current data.
    Archer DF
    J Reprod Med; 2007 Feb; 52(2 Suppl):159-64. PubMed ID: 17477110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of drospirenone/estrogen combinations on bone metabolism.
    Christiansen C
    Climacteric; 2005 Oct; 8 Suppl 3():35-41. PubMed ID: 16203654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens?
    Motivala A; Pitt B
    Drugs; 2007; 67(5):647-55. PubMed ID: 17385938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone.
    Shulman LP
    J Womens Health (Larchmt); 2006 Jun; 15(5):584-90. PubMed ID: 16796485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.